CRN on Davis bill
This article was originally published in The Tan Sheet
Executive Summary
New legislation authorizing FDA to consider a dietary supplement's "unreasonable risk" in light of the level of its benefit would reverse the basic tenets of DSHEA, according to the Council for Responsible Nutrition. HR 3156, introduced June 30 by Rep. Carolyn Davis (D-Calif.), also would "codify FDA's risk/benefit rationale for removing ephedra from the market that was invalidated by the court in Nutraceutical v. Crawford," CRN maintains. The bill contains a provision establishing that in the absence of a sufficient benefit, the presence of even a relatively small risk of serious adverse health effect to a user may be considered unreasonable (1"The Tan Sheet" July 1, 2005, In Brief)...
You may also be interested in...
“Unreasonable risk” bill
HHS Secretary would be granted greater authority to deem a dietary supplement's risk "unreasonable" under a bill introduced June 30 by Rep. Susan Davis (D-Calif.) and cosponsored by Reps. Henry Waxman (D-Calif.) and John Dingell (D-Mich.). The "Dietary Supplement Access & Awareness Act" (H.R. 3156) provides that in certain court procedures, the Secretary may consider a supplement's risk to be unreasonable by weighing its potential benefits against possible health risks. "In the absence of a sufficient benefit, the presence of even a relatively small risk of a serious adverse health effect to a user may be considered" unreasonable, the legislation states. The provision is new to the bill, which otherwise mirrors H.R. 3377, introduced by Davis in October 2003 (1"The Tan Sheet" Nov. 3, 2003, p. 13)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.